首页
400-620-6333
切换导航
搜索
基本信息
| 产品名称 | atezolizumab |
|---|
产品属性
| CAS编号和信息 | Ab175458 |
|---|
数据库链接
| IMGT/mAb-DB | 526 |
|---|---|
| Wikipedia | Atezolizumab |
关联配体
| Ligand ID | 7990 |
|---|---|
| 名称 | atezolizumab |
| 别名 | MPDL3280A |
| 类别 | Antibody |
| 学名 | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide |
| 生物活性评价 |
The development and use of atezolizumab is claimed in patent US8217149 |
| 评价 |
Atezolizumab (MPDL3280A) is a monoclonal antibody directed against programmed death-1 ligand-1 (PD-L1, aka CD274), an important immunopharmacological drug discovery target in immuno-oncology. Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequence analysis using the light chain variable region of atezolizumab provides a 100% match to sequence 21 from patent US8217149. An X-ray crystal structure of the PD-L1/atezolizumab complex has been submitted to the RCSB PDB (accession 5X8L) |
| 配体家族 | Immune checkpoint modulators |
| 单字母多肽序列 | |
| 三字母多肽序列 | |
| 翻译后修饰 | |
| 化学修饰 | |
| 临床描述 |
This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death?ligand 1 [anti-PD-L1] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Participants were randomized 1:1 to receive either docetaxel or atezolizumab. Treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression. This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared with treatment with carboplatin+paclitaxel+bevacizumab in chemotherapy-na?ve participants with Stage IV non-squamous NSCLC. Participants will be randomized in a 1:1:1 ratio to Arm A (Atezolizumab+Carboplatin+Paclitaxel), Arm B (Atezolizumab+Carboplatin+Paclitaxel+Bevacizumab), or Arm C (Carboplatin+Paclitaxel+Bevacizumab). This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study was designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin plus (+) etoposide compared with treatment with placebo + carboplatin + etoposide in chemotherapy-naive participants with ES-SCLC. Participants will be randomized in a 1:1 ratio to receive either atezolizumab + carboplatin + etoposide or placebo + carboplatin + etoposide on 21-day cycles for four cycles in the induction phase followed by maintenance with atezolizumab or placebo until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until persistent radiographic PD or symptomatic deterioration. |
| 来源公司 |
Hoffmann-La Roche Hoffmann-La Roche Hoffmann-La Roche |
参考文献
| 1. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC et al.. (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.. Lancet, 389 (10066): (255-265). [PMID:27979383] |
| 2. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS. (2017) Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.. Sci Rep, 7 (1): (5532). [PMID:28717238] |
| 3. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F et al.. (2018) Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.. N Engl J Med, 378 (24): (2288-2301). [PMID:29863955] |
| 4. Horn L, Mansfield AS, Szcz?sna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M et al.. (2018) First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.. N Engl J Med, 379 (23): (2220-2229). [PMID:30280641] |
| 5. Pardoll DM. (2012) The blockade of immune checkpoints in cancer immunotherapy.. Nat Rev Cancer, 12 (4): (252-64). [PMID:22437870] |
| 6. Topalian SL, Drake CG, Pardoll DM. (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy.. Cancer Cell, 27 (4): (450-61). [PMID:25858804] |
产品问答
产品问答
上海阿拉丁生化科技股份有限公司
? 2016 ALADDIN-E.COM . 版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任
危险品化学品经营许可证（带存储）